Tech Company Financing Transactions
Aclaris Therapeutics Funding Round
On 10/2/2014, Aclaris Therapeutics received $21 million in Series B funding from F-Prime Capital, Sofinnova Ventures and Vivo Capital.
Transaction Overview
Company Name
Announced On
10/2/2014
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series B
Investors
Proceeds Purpose
This financing will enable Aclaris to advance A-101 through to the filing of a new drug application (NDA) with the FDA.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
640 Lee Rd. 200
Wayne, PA 19087
USA
Wayne, PA 19087
USA
Phone
Website
Email Address
Overview
Aclaris Therapeutics, Inc. (ACRS) is a specialty pharmaceutical company focused on identifying, developing and commercializing novel dermatologic treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neal Walker
Chief Financial Officer
Frank Ruffo
Chief Medical Officer
David Gordon
Chief Scientific Officer
Stuart Shanler
VP - General Counsel
Kamil Ali-Jackson
VP - R & D
Joseph Monahan
Browse more venture capital transactions:
Prev: 10/2/2014: Braze venture capital transaction
Next: 10/2/2014: VertiFlex venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs